Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eftilagimod Alpha + Paclitaxel in Chinese Metastatic Breast Cancer
NCT03600090Phase 1Completed
- Sponsor
- EOC Pharma
- Start
- Oct 2018
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eftilagimod alpha in breast cancer, sponsored by EOC Pharma. Primary endpoint: Dose Limiting Toxicity up to 12 months. Started Oct 2018; status: completed.
02
Drugs
eftilagimod alpha
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03600090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600090.